Clinical trials: Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Carcinoma, Non-Small-Cell Lung, Pulmonary Neoplasms
A Phase 2 Trial of Antisense Nucleotide to PKC-Alpha (LY900003, ISIS 3521) Plus Gemcitabine and Carboplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer.
The purposes of this study are to determine the following: Whether LY900003 plus gemcitabine and carboplatin can make your tumor smaller or disappear, and for how long.
- Conditions
- Carcinoma, Non-Small-Cell Lung, Pulmonary Neoplasms, Neoplasms, Lung
- Trial name
- NCT00042679
- Testing
- Gemcitabine, Carboplatin, LY900003
- Where
- 11 sites in United States
- Sponsor
- Eli Lilly and Company
Lung Cancer
Combination Chemotherapy Followed by Radiation Therapy Before Surgery in Treating Patients With Stage IIIB NSCLC
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high energy x-rays to damage tumor cells.
- Trial name
- NCT00030810
- Testing
- Hyperfractionated, Taxotere/Cisplatin, conventional surgery
- Where
- Switzerland
- Volunteers
- 46 people
- Sponsor
- Swiss Cancer Institute
Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
This is a phase 1 dose escalation trial of ZM008, an anti-LLT1 antibody as a single agent followed by combination with Toripalimab in patients with advanced solid tumors who have exhausted all standard therapy available or are…
- Conditions
- Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Pancreas Adenocarcinoma, Biliary Tract Cancer
- Trial name
- NCT06451497
- Testing
- ZM008
- Where
- 3 sites in United States
- Volunteers
- 100 people
- Sponsor
- Zumutor Biologics Inc.
Head and Neck Cancer, Cervical Cancer
A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors
TScan Therapeutics is developing cellular therapies across multiple solid tumors in which autologous T cells are engineered to express a T cell receptor that recognizes tumor-associated antigens presented on specific Human…
- Conditions
- Head and Neck Cancer, Cervical Cancer, Non Small Cell Lung Cancer, HPV16 Related Cancers
- Trial name
- NCT05812027
- Testing
- Tumor and HLA Profiling
- Where
- 21 sites in United States
- Volunteers
- 1,150 people
- Sponsor
- TScan Therapeutics, Inc.
Breast Cancer, Colorectal Cancer
A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies
ATRC-101-A01 is a Phase 1b, open-label dose escalation and expansion trial of ATRC-101, an engineered fully human immunoglobulin G, subclass 1 (IgG1) antibody derived from a naturally occurring human antibody.
- Conditions
- Breast Cancer, Colorectal Cancer, Ovarian Cancer, Non-Small Cell Lung Cancer
- Trial name
- NCT04244552
- Testing
- ATRC-101, Pembrolizumab, Pegylated liposomal doxorubicin (PLD)
- Where
- 19 sites in United States
- Volunteers
- 87 people
- Sponsor
- Atreca, Inc.
Carcinoma, Large Cell, Carcinoma, Non-Small-Cell Lung
Trial Of CP-751, 871 And Erlotinib In Refractory Lung Cancer
The objective of this study is to test a clinical benefit of the addition of CP 751,871 to erlotinib therapy in patients with advanced NSCLC of non adenocarcinoma histology. The primary endpoint is Overall Survival (OS).
- Conditions
- Carcinoma, Large Cell, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Carcinoma, Adenosquamous Cell
- Trial name
- NSCLC (NCT00673049)
- Testing
- CP 751,871 (Figitumumab), Erlotinib
- Where
- 175 sites in United States, Belgium and 25 more
- Volunteers
- 583 people
- Sponsor
- Pfizer
Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Neoplasms
A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers
In this study, adults with non-small-cell lung cancer (NSCLC), triple-negative breast cancer (TNBC) and squamous-cell carcinoma of the head and neck (SCCHN) will be treated with TAK-676 and pembrolizumab following radiotherapy.
- Conditions
- Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Neoplasms, Squamous Cell Carcinoma of Head and Neck
- Trial name
- NCT04879849
- Testing
- Pembrolizumab, TAK-676, Image-guided radiation therapy
- Where
- 5 sites in United States
- Volunteers
- 34 people
- Sponsor
- Takeda
Carcinoma, Non-Small-Cell Lung
Study of Motesanib (AMG 706) in Combination With Paclitaxel and Carboplatin for Advanced Non-Squamous Non-Small Cell Lung Cancer
This study will evaluate progression free survival (PFS), overall survival (OS), objective response rate (ORR), duration of response, and safety of motesanib (AMG706) in combination with paclitaxel and carboplatin compared to…
- Trial name
- NCT02629848
- Testing
- Motesanib, Paclitaxel, Carboplatin
- Volunteers
- 401 people
- Sponsor
- Takeda
Cancer, Tumor, Solid
Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer
This is a Phase 1/2, open-label, multi-center, first-in-human, dose escalation and cohort expansion study evaluating multiple doses and schedules of subcutaneously administered JK08 in patients with unresectable locally, advanced…
- Conditions
- Cancer, Tumor, Solid, Advanced Solid Tumor, Metastatic Cancer
- Trial name
- NCT05620134
- Testing
- JK08, Pembrolizumab, Lenvatinib Pill
- Where
- 11 sites in Belgium, Spain
- Volunteers
- 263 people
- Sponsor
- Salubris Biotherapeutics Inc
Metastatic Cancer, Recurrent Cancer
IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors
This study is to determine the safety of IRX-2 Regimen combined with Nivolumab in patients with recurrent metastatic solid tumors.
- Conditions
- Metastatic Cancer, Recurrent Cancer, Solid Tumor, Renal Cell Carcinoma
- Trial name
- NCT03758781
- Testing
- IRX 2, Nivolumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Metastatic Non-Squamous Non-Small Cell Lung Carcinoma
Pembrolizumab in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer
This phase II trial studies how well pembrolizumab works in treating patients with non-squamous non-small cell lung cancer which has spread to other places in the body.
- Trial name
- NCT02955758
- Testing
- Pembrolizumab
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Joel Neal
Carcinoma, Non-Small-Cell Lung
TAilored Post-Surgical Therapy in Early Stage NSCLC
Our hypothesis is that patients receiving therapy based on their baseline tumor ERCC1 levels and EGFR mutations would attain better disease free survival rates than patients in the control arm receiving noncustomized therapy.
- Trial name
- TASTE (NCT00775385)
- Testing
- Standard Chemotherapy, Customized Treatment
- Where
- 42 sites in France
- Volunteers
- 152 people
- Sponsor
- Intergroupe Francophone de Cancerologie Thoracique
Lung Cancer
Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT01107626
- Testing
- Paclitaxel, Carboplatin, Bevacizumab
- Where
- 434 sites in United States
- Volunteers
- 1,516 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Carcinoma, Non-Small-Cell Lung
A Study of Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer
This is an open-label, single-arm, phase II, multicenter study designed to evaluated the efficacy and safety of atezolizumab in combination with bevacizumab in PD-L1-selected patients with Stage IIIB-IV Non-Squamous NSCLC…
- Trial name
- NCT04426825
- Testing
- Atezolizumab, Bevacizumab
- Where
- 10 sites in China
- Volunteers
- 23 people
- Sponsor
- Hoffmann-La Roche
Metastatic Non-small Cell Lung Cancer (NSCLC), Non-squamous NSCLC
A Study of ABP 215 Versus Bevacizumab in Chinese Subjects With Advanced Non-Squamous Non-Small Cell Lung Cancer
The purpose of this research study is to assess the efficacy and safety of ABP 215 compared to Bevacizumab in Chinese patients with advanced non-small cell lung cancer (NSCLC).
- Trial name
- NCT04466917
- Testing
- ABP 215, Bevacizumab, Paclitaxel
- Sponsor
- Amgen
Squamous Cell Carcinoma of Head and Neck, Colo-rectal Cancer
A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)
This is a first in human, multicenter, open label, Phase 1a and 1b dose-escalation and dose-expansion study to establish the maximum tolerated dose, recommended Phase 2 dose, and evaluate the safety and tolerability of QD oral…
- Conditions
- Squamous Cell Carcinoma of Head and Neck, Colo-rectal Cancer, Non Small Cell Lung Cancer, Transitional Cell Carcinoma of the Bladder
- Trial name
- NCT05121948
- Testing
- HC-7366
- Where
- 7 sites in United States
- Volunteers
- 35 people
- Sponsor
- HiberCell, Inc.
Non Small Cell Lung Cancer, Immune Checkpoint Inhibitor
A Prospective Study of Pembrolizumab Combining Chemotherapy in Advanced NSCLC Patients With EGFR Exon 21 Point Mutation.
A phase II, single-arm, open-label study evaluating efficacy, safety and feasibility of combined chemotherapy and pembrolizumab as first line therapy and Osimertinib as second line therapy in advanced non squamous NSCLC adult…
- Conditions
- Non Small Cell Lung Cancer, Immune Checkpoint Inhibitor, EGFR Exon 21 Mutation
- Trial name
- NCT06142617
- Testing
- Pembrolizumab, pemetrexed, platinum, Osimertinib
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Peking Union Medical College Hospital
Non Small Cell Lung Cancer, Non-Squamous Non-Small Cell Lung Cancer
Similar Efficacy, Safety, and Immunogenicity of FYB206 in Comparison to Keytruda as add-on to Chemotherapy in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC)
NSCLC is the most common type of lung cancer. Metastatic cancers are cancers that start to spread to other parts of the body. NSCLC is treated by radiation therapy, with medicines, surgery, or immunotherapy.
- Trial name
- Lotus (NCT06643117)
- Testing
- FYB206, Keytruda
- Where
- 13 sites in Georgia, Malaysia and 1 more
- Volunteers
- 25 people
- Sponsor
- Formycon AG
Advanced Non-squamous Non-small Cell Lung Cancer
Efficacy and Safety of Use of Platinum Based Doublet Chemotherapy Plus Antiangiogenesis and Immune Checkpoint Inhibitors in Patients With Advanced Non-squamous Non-small Cell Lung Cancer
The purpose of this study is to explore the efficacy and safety of Use of Platinum Based Doublet Chemotherapy Plus Antiangiogenesis and Immune Checkpoint Inhibitors in Patients With Advanced Non-squamous Non-small Cell Lung Cancer
- Trial name
- NCT04137588
- Testing
- Antiangiogenesis Agents, Immune checkpoint inhibitor
- Where
- China
- Volunteers
- 126 people
- Sponsor
- Peking University Cancer Hospital & Institute
Head and Neck Cancer, Lung Cancer
Paclitaxel and Cisplatin Plus Radiation Therapy Followed by Filgrastim in Treating Patients With Recurrent Head and Neck Cancer or Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00021333
- Testing
- filgrastim, cisplatin, paclitaxel
- Where
- 18 sites in United States
- Volunteers
- 29 people
- Sponsor
- Fox Chase Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.